CAR T cell therapy targeting CD19: Clinical trial data
Data from a clinical trial in patients with advanced CD19-positive malignancies after hematopoietic stem cell transplantation (HSCT) showed that 7 patients with advanced non-Hodgkin’s lymphoma (NHL) treated with Ziopharm’s CAR T therapy targeting CD19 using autologous cells had 3-year progression-free survival (PFS) and overall survival (OS) rates of 83% and 100%, respectively. Additionally, 6 patients remained in complete remission at a median follow-up of 25.5 months.
In 19 patients with advanced acute lymphoblastic leukemia (ALL) and NHL treated with Ziopharm’s CAR T cell therapy targeting CD19 using allogenic cells after HSCT, the 1-year PFS and OS rates were 53% and 63%, respectively. Of 8 patients who received allogeneic T cells after haploidentical HSCT, 6 patients remained in complete remission after a median follow-up of 5.2 months and the 1-year PFS and OS rates were 75% and 100%, respectively. No infusion-related or late toxicities were observed. A mild elevation in cytokines was observed without cytokine storm. Autologous and allogeneic cells survived an average of 201 and 51 days, respectively. Data were presented at the American Society of Hematology meeting in Orlando. ...